Transcatheter Tricuspid Valve Replacement Systems: A Case Study in Health Canada Class IV Medical Device Regulation

Read full text Summarise with VIRAT
Authors: Yash Shah, Peivand Pirouzi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Transcatheter tricuspid valve replacement (TTVR) systems represent a first-in-class therapeutic approach for patients with symptomatic severe tricuspid regurgitation, a condition historically undertreated due to high surgical risk in affected patient populations. These minimally invasive devices enable complete valve replacement through catheter-based delivery without open-heart surgery, offering treatment options for patients ineligible for conventional surgical intervention. As permanently implanted cardiovascular prostheses directly contacting the central circulatory system, TTVR systems are classified as Class IV medical devices under Health Canada's Medical Devices Regulations, requiring Medical Device Licence Application (MDLA) with comprehensive safety and effectiveness evidence. This article examines the regulatory framework for TTVR systems using a case study approach, analyzing classification rationale under Schedule 1 rules, regulatory strategy leveraging international approval data, applicable standards, clinical evidence requirements, and Health Canada-specific submission considerations. Keywords: transcatheter valve replacement, tricuspid regurgitation, Class IV medical device, MDLA, Health Canada, structural heart, FDA, PMA, ISO 13485, project management

Fields of Study & Subjects

Healthcare Regulation Cardiac Valve Diseases and Treatments Orthopaedic implants and arthroplasty

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN